Nutriband
Open
$3.88
Prev. Close
$3.88
High
$3.88
Low
$3.88
Market Snapshot
$45.61M
-1.3
-0.71
$2.02M
13
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
emptyResult
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Recently from Cashu
Nutriband Inc. Sells Subsidiary Pocono Pharmaceutical to Focus on Core Business Goals
Nutriband's Strategic Shift: Focusing on Core Competencies through a Major Subsidiary Sale Nutriband Inc. solidifies its commitment to operational efficiency and its core business focus with the annou…
Nutriband (NTRB) Divests Pocono Pharmaceutical to Focus on Core Business and Innovation
Nutriband's Strategic Shift: Focusing on Core Business Areas through Key Divestiture Nutriband Inc. announces a significant agreement to sell a majority stake in its subsidiary, Pocono Pharmaceutical,…
Nutriband Stock Update: Key Developments and Market Insights
Please provide the text you'd like me to summarize, and I'll be happy to help!
Please provide the text you'd like me to summarize.
Please provide the text you'd like me to summarize.